Results 191 to 200 of about 440,316 (302)

Structure and Dynamics of Imidazolium in an Ionic Liquid-PEGDA Iongel via IR, 2D-IR, and NMR Spectroscopy. [PDF]

Chemphyschem
Mukherjee K, Liberatore MR, Parrack TA, Garrett-Roe S.   +3 more
europepmc   +1 more source

Hydraulic and malleable female‐to‐male penile implants after phalloplasty in transgender individuals: a retrospective cohort analysis

BJU International, EarlyView.
Objectives To provide a comprehensive summary of the surgical outcomes of Zephyr Surgical Implants (ZSI; Geneva, Switzerland) hydraulic and malleable female‐to‐male (FTM) penile implants (PIs) in transgender patients. Patients and Methods All transgender patients who underwent hydraulic (ZSI FTM 475) and malleable (ZSI FTM 100) erectile device ...
Maya Levy, Wouter B. van der Sluis, Emma L. van Abbema, Brechje L. Ronkes, R. Jeroen A. van Moorselaar, Mark‐Bram Bouman, Garry L.S. Pigot   +6 more
wiley   +1 more source

Systemic isosporosis (atoxoplasmosis) in American robins (<i>Turdus migratorius</i>) in the southeastern United States. [PDF]

Int J Parasitol Parasites Wildl
Stilz CR, Yabsley MJ, Schlesinger MS, Garrett KB, Kunkel MR, Weyna AAW, Slankard K, Casey C, Hanni D, Nemeth NM.   +9 more
europepmc   +1 more source

Out with the old, in with the new? A retrospective comparison of malleable erectile implants in phalloplasty

BJU International, EarlyView.
Objective To compare the long‐term outcomes of the two main types of malleable erectile implants after phalloplasty in transgender men: models originally designed for cisgender men (conventional models) or the more recently developed Zephyr Surgical Implants (Geneva, Switzerland) female‐to‐male 100 implant (ZSI FtM 100) specifically for phalloplasty ...
Maya Levy, Emma L. van Abbema, Brechje L. Ronkes, Mark‐Bram Bouman, R. Jeroen A. van Moorselaar, Garry L. S. Pigot   +5 more
wiley   +1 more source

Host Aging Induces a Senescent-Like Phenotype in Neutrophils and Altered Transcriptional Responses to Streptococcus pneumoniae. [PDF]

Aging Cell
Battaglia MC, Bhalla M, Marzullo B, Betadpur A, Lenhard AP, Mohamed RH, Kalem MC, Heinzinger LR, Leus PA, Labarron S, Garrett-Sinha LA, Mecsas J, Blumental-Perry A, Bou Ghanem EN.   +13 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

QcrB inhibitor Q203 (Telacebec) can synergize with clofazimine and clarithromycin to control a Mycobacterium avium infection. [PDF]

PLoS One
Cheng Y, Mulvey K, Moraski GC, Tan X, Mizutare T, Miyagawa S, Frey C, Miller MJ, Schorey JS.   +8 more
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

The 'Public' in Public Involvement: A Call to Centre Frontline Staff Voices in Health Workforce Research. [PDF]

Health Expect
Zhao Y, Aunger J, Garrett H, Hewitson P, Davies A, Pareek M, Molyneux S.   +6 more
europepmc   +1 more source

More About Oysters Than You Wanted to Know [PDF]

, 1970
Power, Garrett
core   +1 more source